Literature DB >> 34849705

Myocardial infarction after elective percutaneous coronary intervention-which cardiac troponin cut-off to use?

Kai M Eggers1, Stefan K James1, Bertil Lindahl1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34849705      PMCID: PMC8899530          DOI: 10.1093/eurheartj/ehab805

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


× No keyword cloud information.
This commentary refers to ‘Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data’, by J. Silvain We have read the paper from Silvain et al., recently published in the European Heart Journal, with interest. We congratulate the authors in their success to further clarify the relation between cardiac troponin (cTn) release after elective percutaneous coronary intervention (PCI) and outcome. The authors observed that procedural myocardial injury independently predicted 1-year all-cause mortality with a prognostic threshold at cTn levels ≥3 × 99th percentile. This level is well above the commonly used cTn cut-off to define spontaneous myocardial infarction (MI) but below the ≥5 × 99th percentile cut-off incorporated in the definition of procedural MI, i.e. Type 4a MI., The data presented by Silvain et al. raise the question whether a cTn cut-off lower than ≥5 × 99th percentile might be equally prognostic in patients fulfilling non-cTn criteria for Type 4a MI, i.e. clinical or electrocardiographic signs of myocardial ischaemia, imaging evidence of loss of viable myocardium or procedural disruption of coronary blood flow. A spline chart similar to the Take home figure in the original publication would be helpful. We are aware that such an analysis may be hampered by smaller patient numbers with available clinical information in the dataset. However, extrapolating the data reported for procedural myocardial injury, at least 1000 patients would have been labelled Type 4a MI if using cTn ≥1 × 99th percentile as cut-off. Proof of prognostic significance of such smaller cTn release magnitudes will have important implications on the management of patients sustaining clinically relevant myocardial ischaemia during elective PCI. Conflict of interest: none declared.
  3 in total

1.  Fourth Universal Definition of Myocardial Infarction (2018).

Authors:  Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Bernard R Chaitman; Jeroen J Bax; David A Morrow; Harvey D White
Journal:  Circulation       Date:  2018-11-13       Impact factor: 29.690

2.  Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data.

Authors:  Johanne Silvain; Michel Zeitouni; Valeria Paradies; Huili L Zheng; Gjin Ndrepepa; Claudio Cavallini; Dimitri N Feldman; Samin K Sharma; Julinda Mehilli; Sebastiano Gili; Emanuele Barbato; Giuseppe Tarantini; Sze Y Ooi; Clemens von Birgelen; Allan S Jaffe; Kristian Thygesen; Gilles Montalescot; Heerajnarain Bulluck; Derek J Hausenloy
Journal:  Eur Heart J       Date:  2021-01-21       Impact factor: 29.983

3.  Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Authors:  Heerajnarain Bulluck; Valeria Paradies; Emanuele Barbato; Andreas Baumbach; Hans Erik Bøtker; Davide Capodanno; Raffaele De Caterina; Claudio Cavallini; Sean M Davidson; Dmitriy N Feldman; Péter Ferdinandy; Sebastiano Gili; Mariann Gyöngyösi; Vijay Kunadian; Sze-Yuan Ooi; Rosalinda Madonna; Michael Marber; Roxana Mehran; Gjin Ndrepepa; Cinzia Perrino; Stefanie Schüpke; Johanne Silvain; Joost P G Sluijter; Giuseppe Tarantini; Gabor G Toth; Linda W Van Laake; Clemens von Birgelen; Michel Zeitouni; Allan S Jaffe; Kristian Thygesen; Derek J Hausenloy
Journal:  Eur Heart J       Date:  2021-07-15       Impact factor: 29.983

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.